Home Daily Intelligence Tracker
    • Plans Blog Contact
    Aurinia Pharmaceuticals Inc logo
    AUPH

    Aurinia Pharmaceuticals Inc

    MaveScore 36 Low model confidence
    Last Price US$15.78 As of Jul 10, 2026
    DCF Fair Price US$17.28 Research estimate · Jul 10, 2026 +4.1% vs price
    Market Cap US$2.1b Company size context
    7D Performance 1.09% Past 7 days
    1Y Performance 76.71% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    103 days old

    Market price date

    Jul 10, 2026

    2 days old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 36 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    13/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    14/25 Mixed

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    3/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    5/15 Weak

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    1/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Favors positive earnings, positive cash flow, and lower multiples.
    • Highlights research candidates with supportive 3-month and 6-month price regimes.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Aurinia Pharmaceuticals Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It Read More

    Aurinia Pharmaceuticals Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Aurinia Pharmaceuticals Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 07, 2026

    Quarterly result summary

    Revenue was $77.7M (+24% YoY); EPS was $0.25 (+56% YoY).

    Revenue $77.7M +24% YoY
    EPS $0.25 +56% YoY
    Operating income $41.4M +90% YoY
    Net income $34.4M +48% YoY

    What changed

    • Revenue +24% YoY to $77.7M; EPS +56% YoY to $0.25.
    • Operating income +90% YoY to $41.4M.
    • Net income +48% YoY to $34.4M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 8-K May 07, 2026 SEC filing 10-Q May 07, 2026 SEC filing 10-K Feb 26, 2026 SEC filing 8-K Feb 26, 2026 Earnings release Earnings release Feb 26, 2026 SEC filing 8-K Nov 04, 2025 Earnings release Earnings release Nov 04, 2025 Earnings material Earnings release Nov 04, 2025 SEC filing 10-Q Nov 04, 2025 SEC filing 10-Q Jul 31, 2025 Earnings release Earnings release Jul 31, 2025

    Recent News



    New Analyst Forecast: $AUPH Given $21.0 Price Target
    3 hours ago
    Jefferies upgrades Aurinia Pharmaceuticals stock to Buy on strong Lupkynis sales
    6 hours ago
    Is AUPH stock attractive for hedge funds - Market Activity Summary & Capital Efficiency Focused Strategies
    6 hours ago

    Earnings Per Share

    Score 4.00/5
    Aurinia Pharmaceuticals Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.77/5
    Aurinia Pharmaceuticals Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Aurinia Phar... AUPH US$2.1b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.41/5
    Aurinia Pharmaceuticals Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Aurinia Phar... AUPH US$2.1b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 3.68/5
    Aurinia Pharmaceuticals Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Aurinia Phar... AUPH US$2.1b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Aurinia Pharmaceuticals Inc logo

    Aurinia Pharmaceuticals Inc

    US$15.78

    US$17.28

    +4.1% vs price

    US$2.1b

    1.09%

    76.71%